Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Combination treatment modalities in cutaneous T-cell lymphoma (CTCL)
Joan Guitart
*
*
Corresponding author for this work
Dermatology
Research output
:
Contribution to journal
›
Article
›
peer-review
12
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Combination treatment modalities in cutaneous T-cell lymphoma (CTCL)'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Treatment Modalities
100%
Cutaneous T-cell Lymphoma
100%
Combination Treatment
100%
Bexarotene
66%
Quality of Life
33%
Clinical Practice
33%
Novel Mechanism
33%
Therapeutic Outcome
33%
Mechanism of Action
33%
Treatment Options
33%
New Treatment Options
33%
Unique Mechanism
33%
Selective Antagonist
33%
Monotherapy
33%
Duration of Response
33%
Topical Therapy
33%
Phototherapy
33%
Lymphoma Therapy
33%
Retinoid X Receptor
33%
Combined Modality
33%
Combination Chemotherapy
33%
Combination Treatment Strategy
33%
Chemotherapy Combinations
33%
Combined Treatment Modalities
33%
Therapy-systemic
33%
Medicine and Dentistry
Cutaneous T Cell Lymphoma
100%
Bexarotene
66%
Chemotherapy
33%
Monotherapy
33%
Topical Treatment
33%
Phototherapy
33%
Combination Chemotherapy
33%
Quality of Life
33%
Retinoid X Receptor
33%
Pharmacology, Toxicology and Pharmaceutical Science
Cutaneous T Cell Lymphoma
100%
Chemotherapy
66%
Bexarotene
66%
Monotherapy
33%
Retinoid X Receptor
33%